Objective: To evaluate how antireflux surgery influences the risk of esophageal cancer in patients with gastroesophageal reflux disease (GERD) and Barrett esophagus. Background: GERD is a major risk factor for esophageal adenocarcinoma, and the United Kingdom has the highest incidence of esophageal adenocarcinoma globally. Methods: Hospital Episode Statistics database was used to identify all patients in England aged over 18 years diagnosed with GERD with or without Barrett Esophagus from 2000 to 2012, with antireflux surgery being the exposure investigated. The Clinical Practice Research Datalink (CPRD) was used to provide a sensitivity analysis comparing proton pump inhibitor therapy and antireflux surgery. Hazard ratios (HR) with 95% confidence intervals (CI) were calculated using Cox proportional hazards model with inverse probability weights based on the probability of having surgery to adjust for selection bias and confounding factors. Results: (i) Hospital Episode Statistics analysis; among 838,755 included patients with GERD and 28,372 with Barrett esophagus, 22,231 and 737 underwent antireflux surgery, respectively. In GERD patients, antireflux surgery reduced the risk of esophageal cancer (HR ¼ 0.64; 95% CI 0.52-0.78). In Barrett esophagus patients, the corresponding HR was (HR ¼ 0.47; 95% CI 0.12-1.90).
The mechanism of the neoplastic process is GERD leading to oesophagitis and metaplastic change in the squamous esophageal epithelium to Barrett esophagus and progression with dysplastic changes and then eventually to esophageal adenocarcinoma. 7, 8 The mainstay of treatment for GERD is medical with proton pump inhibitors (or H2 antagonists), but antireflux surgery is an alternative, usually performed as a laparoscopic partial or total fundoplication. 9 Randomized trials have provided conflicting results when comparing proton pump inhibitor therapy and antireflux surgery in the long-term control of GERD symptoms. 10, 11 However, in recent years, an increasing volume of literature is being published concerning the potential long-term adverse effects of sustained proton pump inhibitor therapy use, including dementia, long-bone fractures, and gastric adenocarcinoma. [12] [13] [14] Previous publications have failed to demonstrate a clear consistent benefit of antireflux surgery in reducing the risk of esophageal adenocarcinoma compared to medical therapy. 15, 16 However these publications have been limited by small sample sizes, with low numbers of esophageal adenocarcinoma in the long-term followup categories, and poorly defined control populations specifically regarding severity of reflux. 16 The present study seeks to overcome the power limitations as the United Kingdom has the highest Incidence of esophageal adenocarcinoma globally. Furthermore, this study utilized two datasets comparing proton pump inhibitor therapy with antireflux surgery, and also evaluate a Barrett's esophagus population.
The primary objective of this study was to examine how antireflux surgery influences the risk of esophageal cancer in GERD patients. The secondary objectives were to evaluate esophageal cancer risk following antireflux surgery in Barrett esophagus patients and to provide a subset comparison of esophageal cancer risk for patients receiving standard-dose proton pump inhibitor therapy with antireflux surgery.
METHODS

Design
This was a national population-based cohort study of antireflux surgery conducted in England during the period 2000 to 2012 with follow-up until 2014. Antireflux surgery was the main exposure and esophageal cancer was the main outcome. Permissions for the comparison of anonymized administrative data were obtained from the National Information Governance Board for Health and Social From the Data were derived from the Hospital Episode Statistics (HES) database. 17 This is a record-based system that collects patient-level data from all National Health Service (NHS) hospitals in England. It captures all patients treated in public sector hospitals and all patients treated in privately funded institutions. Patients are given a unique HES identifier that allows all of their hospital admissions to be tracked. The study population consisted of patients aged 18 years or older with a diagnosis of GERD as identified from the International Classification of Diseases version 10 (ICD-10) codes K210 and K219, and patients with Barrett esophagus using the ICD-10 code K227. Patients receiving antireflux surgery were identified using the Office of Population Censuses and Surveys Classification of Surgical Operations and Procedures 4th revision (OPCS-4) codes; primary antireflux surgery (G242-G245, G248, and G249) and revisional antireflux surgery (G251, G258, G259). Risk of esophageal cancer (ICD-10 codes C15 and D001) was compared between GERD and Barrett esophagus patients receiving antireflux surgery and those not receiving such surgery. Starting date was taken as the date of GERD diagnosis for both surgical and nonsurgical groups.
Because patients undergoing antireflux surgery will represent a group of patients with more severe GERD, a sensitivity analysis was performed by linking the HES with the Clinical Practice Research Datalink (CPRD) datasets to mitigate selection bias.
Clinical Practice Research Datalink (CPRD)
Almost 10% of the English population is registered with practices that enter data into the CPRD, formally the General Practice Research Database. About half of all CPRD practices are linked to inpatient HES data, which contain clinical information for each episode of care in English hospitals. Patient linkage was performed centrally using the National Health Service number. Database coverage was from 1997 to 2010, restricted by the end of cancer registry coverage. In CPRD, medcodes are based on the Read clinical coding system for primary care electronic health records developed in England. The study population consisted of patients aged 18 years or older with a diagnosis of GERD or Barrett esophagus were identified from CPRD data using the relevant Read codes or from the linked HES dataset using the ICD-10 codes described above. Patients undergoing antireflux surgery were identified using the relevant OPCS-4 codes described previously and were compared with patients receiving standard dose proton pump inhibitor therapy defined as at least 40 mg of esomeprazole, omeprazole or pantoprazole or 30 mg of lansoprazole daily for at least 1 year. The CPRD dataset was linked to the National Cancer Registry, which permitted analysis of only esophageal adenocarcinoma in this subset analysis. Risk of esophageal adenocarcinoma was compared among participants with GERD and Barrett esophagus separately receiving antireflux surgery and those receiving standard dose proton pump inhibitor therapy. Starting date was taken as the date of GERD diagnosis for both surgical and proton pump inhibitor treatment groups.
Subset Analyses
Additional analyses were performed:
(i) Comparison of esophageal cancer risk in patients aged 50 years or older receiving antireflux surgery versus no antireflux surgery (HES dataset) or standard dose proton pump inhibitor therapy (CPRD dataset).
(ii) Within the Barrett cohort, comparison of utilization of EMR or HALO following antireflux surgery versus no antireflux surgery (HES dataset) or standard dose proton pump inhibitor therapy (CPRD dataset). (iii) Within the cohort of patients receiving antireflux surgery, analysis of esophageal adenocarcinoma risk in those patients within recurrent reflux (CPRD dataset). This was defined by the requirement standard dose proton pump inhibitor therapy at 6 months after surgery or for revisional antireflux surgery within the study period.
Statistical Analysis
Categorical variables were expressed as percentages, with intergroup comparisons made using x 2 test, and continuous variables were expressed as medians and ranges, with intergroup comparisons made using Mann-Whitney U test. Cox proportional hazards models were fitted to study the long-term esophageal cancer risk in England from both treatment groups. A multivariable model provided hazard ratios (HR) with 95% confidence intervals (CI), adjusted for age (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) 30 -39, 40-49, 50-59, 60-69, 70-79, 80 yrs, and older), sex (male or female), comorbidity (Charlson comorbidity index 0, 1, or !2) and obesity (yes or no). Obesity was defined using the ICD-10 code E66 (HES dataset) or a body mass index of 30 kg/m 2 within 6 months of diagnosis of GERD (CPRD dataset). Inverse probability weights (IPW) were applied to correct for confounding and selection bias. First, a logistic model was fitted to calculate the probability of having an antireflux surgery and the predicted values were used to calculate the inverse probability weights that were afterward applied in the logistic models for esophageal cancer models. Survival curves were also obtained using the inverse probability weights. 18 Statistical analysis was performed using SPSS version 22.0 software (Statistical Package for the Social Sciences software, Version 22, SPSS, Chicago, IL) and using SAS version 9 4 (SAS Institute, Cary, NC) and R 3.3.2 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Hospital Episode Statistics Analysis
GERD Patients Aged 18 Years or Older Receiving Antireflux Surgery Versus No Such Surgery
Over the study period, 838,755 patients aged 18 years or older were diagnosed with GERD and included, of these 22,231 (2.7%) underwent antireflux surgery. Patients undergoing antireflux surgery were younger (median age 47 vs. 59 years; P < 0.01), more commonly male (56% vs. 52.3%; P < 0.01) and obese (6.1% vs. 4.2%; P < 0.01), and less commonly having Charlson score of !2 (1.6% vs. 3.3%; P < 0.01) ( Table 1 ). The median follow-up period was 5.4 and 6.4 years in antireflux surgery and non-surgery groups. Antireflux surgery was associated with a reduced risk of esophageal cancer (adjusted HR 0.64; 95% CI 0.52-0.78) ( Table 2) (Fig. 1 ).
Barrett Esophagus Patients Aged 18 Years or Older Receiving Antireflux Surgery Versus No Such Surgery
Over the study period, 28,372 patients aged 18 years or older were diagnosed with Barrett esophagus and were included, and 737 (2.6%) underwent antireflux surgery. Similar to the GERD cohort, patients with Barrett esophagus undergoing antireflux surgery were younger, more commonly obese and less commonly had Charlson score of !2 ( Table 1 ). The median follow-up period was 5.6 and 4.9 years in antireflux surgery and nonsurgery groups, respectively. Antireflux surgery was associated with decreased point estimates of esophageal cancer (adjusted HR 0.47; 95% CI 0.12-1.90) ( Table 2) (Fig. 2 ).
Within the Barrett cohort the proportion of patients requiring EMR or HALO was similar following antireflux surgery (0.90%, 7 from 775 patients) compared with no antireflux surgery (1.59%, 439 from 27683 patients) (P ¼ 0.442).
Subset Analysis: GERD Patients Aged 50 Years or Older Receiving Antireflux Surgery Versus No Such Surgery
Over the study period, 580,293 patients aged 50 years or older were diagnosed with GERD in HES. Of these, 9753 patients (1.7%) underwent antireflux surgery. The median follow-up period was 5.4 and 6.4 years in antireflux surgery and nonsurgery groups, respectively. Antireflux surgery was associated with a reduced risk of esophageal cancer (adjusted HR 0.75; 95% CI 0.58-0.97) ( Table 2 ).
Subset Analysis: Barrett Esophagus Patients Aged 50 Years or Older Receiving Antireflux Surgery Versus No Such Surgery
Over the study period, 22,901 patients aged 50 years or older were diagnosed with Barrett esophagus. Of these 432 patients (1.9%) received antireflux surgery. The median follow-up period was 5.6 and 4.9 years in antireflux surgery and nonsurgery groups, respectively. Antireflux surgery was associated with decreased point estimates of esophageal cancer (adjusted HR 0.76; 95% CI 0.19-3.09), but statistically nonsignificant (Table 2) (Fig. 2) .
Clinical Practice Research Datalink Analysis
GERD Patients Aged 18 Years or Older Receiving Antireflux Surgery Versus Standard-dose Proton Pump Inhibitor Therapy
16,398 patients aged over 18 years with GERD and on standard-dose proton pump inhibitor therapy were included in this analysis. From this cohort 1116 patients (6.6%) underwent antireflux surgery with the remaining 15,822 patients having proton pump inhibitor therapy alone. The median followup period was 5.2 and 5.3 years in antireflux surgery and proton pump inhibitor therapy groups, respectively. Patients undergoing antireflux surgery were younger (median age 48 vs. 60 yrs; P < 0.01), more commonly male (50.2% vs. 43.3%; P < 0.01) and less commonly having Charlson score of !2 (9.1% vs. 20.9%; P < 0.01), however there was no significant difference in the incidence of obesity between groups (2.1% vs. 2.5%; P ¼ 0.39). The prevalence of esophageal adenocarcinoma was decreased following antireflux surgery, but was not statistically significant (0% vs. 0.2%; P ¼ 0.16). No esophageal adenocarcinoma events were identified in the antireflux surgery cohort, which prevented the calculation of hazard ratios for this result.
Barrett Esophagus Patients Aged 18 Yes or Older Receiving Antireflux Surgery Versus Standard-dose Proton Pump Inhibitor Therapy
Over the study period, 786 patients aged over 18 years with Barrett esophagus were included in this analysis. From this cohort 166 patients (21.1%) underwent antireflux surgery and 620 patients (78.9%) were treated with proton pump inhibitor treatment, of these 3 (1.8%) and 18 (2.9%) patients were diagnosed with esophageal cancer during the study period respectively. The median follow-up period was 5.8 years in both groups. Patients undergoing antireflux surgery were younger (median age 52 vs. 64 yrs; P < 0.01), less commonly male (59.0% vs. 66.0%; P ¼ 0.10) and with Charlson score of !2 (9.0% vs. 19.4%; P < 0.01), however there was no significant difference between the groups in the incidence of obesity (1.8% vs. 1.1%; P ¼ 0.49). Antireflux surgery was followed by a decreased point estimate of esophageal adenocarcinoma, but this was not statistically significant (adjusted HR ¼ 0.75; 95% CI 0.21-2.63) (Fig. 3) .
Sixteen patients (2.0%) underwent HALO or EMR after the first recording of reflux or antireflux surgery. Of these 2 (1.2%) underwent antireflux surgery and the remaining 14 patients (2.3%) received standard dose proton pump inhibitor only (P ¼ 0.32). 
Subset Analysis: GERD Patients Aged 50 Years or Older Receiving Antireflux Surgery Versus Standard-dose Proton Pump Inhibitor Therapy
11,727 patients aged over 50 years with GERD and on standard-dose proton pump inhibitor therapy were included in this analysis. From this cohort 518 patients (4.4%) underwent antireflux surgery with the remaining 11,209 patients having proton pump inhibitor therapy alone. The median follow-up period was 5.2 and 5.3 years in antireflux surgery and proton pump inhibitor therapy groups, respectively. The prevalence of esophageal adenocarcinoma was decreased following antireflux surgery, but was not statistically significant (0% vs. 0.2%; P ¼ 0.26). No cancer events were identified in the antireflux surgery cohort, which prevented the calculation of hazard ratios for this result.
Subset Analysis: Barrett Esophagus Patients Aged 50 years or Older Receiving Antireflux Surgery Versus Standard-dose Proton Pump Inhibitor Therapy
Over the study period, 622 patients aged over 50 years with Barrett esophagus were included in this analysis. From this cohort 92 patients (14.8%) underwent antireflux surgery and 530 patients (85.2%) were treated with standard dose proton pump inhibitor treatment, of these 3 (3.3%) and 18 (3.4%) patients were diagnosed with esophageal adenocarcinoma during the study period, respectively. The median follow-up period was 5.5 and 5.7 years in antireflux surgery and proton pump inhibitor treatment groups, respectively. Antireflux surgery was followed by a decreased point estimate of esophageal adenocarcinoma, but this was not statistically significant (adjusted HR ¼ 0.77; 95% CI 0.21-2.78).
Subset Analysis: Patients With Recurrent Reflux Following Antireflux Surgery
From 2000 to 2010, 1116 patients underwent antireflux surgery, of whom 335 (30.0%) were on proton pump inhibitor therapy 6 months after surgery and 51 (4.6%) underwent revisional antireflux surgery. No cancer events were noted in either group.
DISCUSSION
This large population-based cohort study suggests that patients with GERD who undergo antireflux surgery are at a reduced risk of esophageal cancer when compared with nonoperated patients with GERD. Although limited by low statistical power, also when compared with GERD patients on proton pump inhibitor therapy, antireflux surgery suggested a decreased risk of esophageal cancer, and similar indications were found for patients with Barrett esophagus.
The results of this study contradict some previous national population-based cohort studies, which showed that antireflux surgery does not consistently reduce the risk of esophageal adenocarcinoma compared to medical therapy in patients with GERD. [19] [20] [21] This might be a reflection of the large sample size studied and the relatively high incidence of esophageal cancer within the population studied, compared to previous publications. When considering the clinical implications of this study, the long-term adverse effects of proton pump inhibitor use must also be considered in patients with chronic GERD. [12] [13] [14] These adverse outcomes must be balanced against the short-term and long-term complications of antireflux surgery, although recent data does suggest that antireflux surgery is a very safe procedure with a 30-day mortality rate of 0.03%. 22 The main analysis from the present study to demonstrate a statistically significant reduction in esophageal cancer risk was seen in the very large cohort including over 800,000 patients with over 20,000 patients receiving ARS. This does suggest the absolute reduction in esophageal cancer risk from antireflux surgery is small and requires a large number of patients to be studied in order to demonstrate any statistically significant reduction. In this study, patients with Barrett esophagus were also studied as a population at increased risk of developing esophageal adenocarcinoma. 23 Although hampered by low precision, when GERD severity was accounted for by comparison of proton pump inhibitor therapy with antireflux surgery, there were similar reductions in the risk esophageal cancer associated with antireflux surgery, which again contradicts results from previous studies. [24] [25] [26] The mechanism of the reduced cancer risk seen with antireflux surgery when compared with nonsurgical or medical treatment of GERD is multifactorial. Anatomically antireflux surgery creates a barrier against the reflux of gastric contents into the lower end of the esophagus reducing the pro-inflammatory and carcinogenic process. 27 Medical treatment mainly does not mechanically prevent reflux, but does decrease the acidity of the refluxed content. Importantly, previous randomized controlled trials have shown a lower level of esophageal pathological acidity at 5-year followup after antireflux surgery compared with medication. 28 Also antireflux surgery is an intervention that is not dependent upon dose or compliance, which is a limitation of medical therapy for GERD.
The population-based design with virtually complete inclusion of all eligible patients in England is strength of the study. The large sample size, complete follow-up of all patients, and the adjustment for several relevant confounding factors are other advantages. There are also limitations. The reliability of the methodology and accuracy of data collection is a limitation of most national administrative databases. From the national dataset utilized it was not possible to identify the diagnostic workup for GERD, including use of pH studies, which may have shown heterogeneity across the country. Patients receiving antireflux surgery often have failed medical therapy and thus often have a more severe form of GERD, suggesting a potential selection bias of the HES analysis. However, this selection bias was reduced in the CPRD analysis comparing patients on proton pump inhibitor therapy with antireflux surgery. An additional subset analysis was also performed on patients aged 50 years and older to reduce any selection bias demonstrating similar findings, because younger patients maybe more likely to receive antireflux surgery. 29 Furthermore, although all analyses were adjusted for patient age, sex, obesity, and comorbidity, there may have been unmeasured factors, which may have confounded the results. The incidence of esophageal cancer was low within the study cohort, but yet greater than previous publications in this field, 16 because of the relatively high incidence of esophageal adenocarcinoma in England. 4 Yet, the statistical power was inadequate for the secondary analyses, documented by the wide confidence intervals. However, all analyses consistently indicated reduced risk of esophageal cancer in the antireflux surgery groups, indicating validity.
In conclusion, the results of this national English populationbased cohort study of patients with GERD indicate that antireflux surgery is associated with a reduction in the risk of esophageal cancer. This reduction was suggested also in patients with Barrett esophagus undergoing antireflux surgery. However, the absolute reduction is small and therefore patients should be counseled that antireflux surgery is primarily an operation for symptomatic relief from GERD.
DISCUSSANTS
Philippe Nafteux (Leuven, Belgium):
I would like to start by thanking the authors for this quite interesting paper, which looks at the impact of antireflux surgery on the development of adenocarcinoma in GERD patients. This study is particularly interesting, as the literature available has not yet provided us with a consistent answer to this question.
I have several questions for you. First, you mentioned that there was a statistically significant decrease in esophageal cancer in the surgery group. In the subset analysis on adenocarcinoma, no statistical significance was recorded. This seems counter-intuitive. How do you explain this change in significance?
Second, did you make the same subanalysis for the squamous cell cancer group and consider risk factors for squamous cell carcinoma as confounders?
Third, looking at the Kaplan-Meier curves (Fig. 1) , the freedom from cancer drops in the nonsurgery group. Especially during the first year, both curves seem to come together at the end of the graph. How do you explain this reduction in freedom from cancer during the first year? Do you really believe the difference is surgery-related?
Fourth, conversely, the freedom from cancer in the Barrett group decreases in the nonsurgery group after 8 years, which could define a real potential effect of the antireflux surgery in the higher risk group. So, I would advocate that we wait for the results to be updated based on a longer follow-up period.
I would like to thank the authors for this very interesting manuscript as well as the ESA for the privilege of being the first discussant of this paper.
Response From Sheraz Markar (London, United Kingdom):
Thank you, Professor Nafteux, for your kind review of the paper and valuable comments. Regarding the first point on the lack of statistical significance in the adenocarcinoma analysis, I think that this is fundamentally an issue of statistical power. The only analysis to demonstrate statistical significance included over 800,000 patients, while the analysis of specifically adenocarcinoma included only 17,000 patients. However, it should be noted that there was still a reduction in the point estimate for the risk of cancer for all subset analyses, including the one for adenocarcinoma, which implies that all of the subset analyses, except the one that included 800,000 patients, may be underpowered.
Regarding your second question about squamous cell cancer, the primary focus of this study was to look at the influence of modulation of reflux on adenocarcinoma risk. So, we didn't look at the squamous cell cancer cohort. However, we are currently undertaking a study on the modulation of achalasia. We are looking at patients receiving endoscopic versus surgical treatment for achalasia and the long-term risk of esophageal cancer, specifically squamous cell cancer. I think that this study will be of great interest in the future.
Regarding your third question on the Kaplan-Meier curves, I think that it is really important to look at them according to the numbers at risk at each of the time points. When you get to the 10-12 year mark, the numbers at risk become quite small because of the follow-up period and censoring of data. In actual fact, when we looked at the yearly difference, the maximal difference was noted between 5 and 7 years after surgery. Now, if you look at Professor Lagergren's original NEJM paper, patients who had reflux symptoms between 5 and 7 years still had an increase risk of cancer with a hazard ratio of 7.5, which does imply that there still may be a merit in the modulation of reflux, even when observed in patients at an early stage.
Regarding your final point about the Barrett group, I think that this is a really good point. I believe that this is something we should definitely look at in the future. The issue is that the Barrett group consists of a very unique cohort of patients, and you really need to be able to evaluate specific aspects of the Barrett, which could be modulated. In the UK, we're actually quite lucky, as we've set up our national Barrett registry over the last 4 years, which we hope will help us complete the study you mentioned in around 10 to 12 years. Thank you very much for this comment and your review.
Arnulf Hölscher (Frankfurt am Main, Germany):
Thank you very much for this interesting presentation. In this context, it is always very important to clarify, whether previous antireflux surgery was effective or not. However, the criteria that you applied for this item were only indirect: redo surgery or postoperative intake of PPI. A functional testing of recurrent reflux or an endoscopic evaluation of esophagitis were not done. Many people take PPI, not only for typical reflux symptoms, such as heartburn, but also for upper abdominal pain or other unspecific symptoms, such as dyspepsia. Could you please comment on this?
A patient with non-functioning fundoplication has to be considered more or less as a patient without surgery. To my knowledge no case has been published in which a patient with reflux disease without Barrett esophagus and effective fundoplication developed an esophageal adenocarcinoma.
Absolutely, I completely agree with you. I think that using national registries or large data sets to try to understand whether or not you cured or symptomatically improved the patient from reflux is a very challenging area. Professor Lagergren has just published a study addressing the failure of antireflux surgery in JAMA, and I used his criteria for the definition in this study. According to his criteria, we identified PPI at 6 months or antireflux surgery as a recurrence of GERD symptoms. However, I completely accept that this may not be a hard end point for this particular analysis.
Giovanni Zaninotto (London, United Kingdom):
Thank you very much for this presentation. I have 2 questions for you. First, did you consider other type of cancers, such as lung cancer and liver cancer, as a proxy for the use of tobacco and alcohol, which could have influenced the increased incidence of esophageal cancer? Second, did you observe any regional variations in the outcome, since the incidence of esophageal cancer is higher in northern England than it is in the southern regions?
To answer your first question, regarding whether we looked at other cancers, the answer is we didn't. In all honesty, the issues around data access, particularly this type of data access, are very complex. So, our ethics are very specific to upper GI disease and upper GI malignancy. However, this may be something to consider in the future.
Regarding your second question on geographical variation, we did adjust for strategic health authority within our analysis, which does account for regional variation within the UK. So, it was factored in the overall analysis.
